- Update highlights proposed acquisitions, product development and growing IP portfolio
- Three new patent filings join established global rights to other patented technologies
- Innovative transdermal delivery technology increases bioavailability of cannabinoids
- Global cannabis market projected to reach $31.4 billion by 2021
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has provided investors an update covering a number of recent achievements and ongoing activities, including the company’s proposed acquisitions of ERS Holdings, LLC and Thrudermic, LLC; its ongoing product development efforts; its growing IP portfolio; its termination of a previously announced standstill agreement; out-licensing of its IP; and its engagement of an established European distribution partner (http://cnw.fm/sB649). In a news release, Dr. Patrick Frankham, CEO of Pivot, stated, “We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes.”
Based in Vancouver, Canada, Pivot Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using proprietary drug delivery platform technologies. By developing and commercializing a number of pharmaceutical-grade formulations for cannabinoid-based consumer health care products, Pivot Pharmaceuticals is positioning itself to capitalize on the impressive growth of the cannabis market. According to market research company Brightfield Group, the marijuana market will experience a CAGR of 60 percent to reach $31.4 billion by 2021 (http://cnw.fm/8Kg16).
As part of its overall growth strategy, Pivot Pharmaceuticals recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office, according to a company press release (http://cnw.fm/J3CsB) issued on February 1, 2018. Its three patents cover:
- Transdermal nanotechnology delivery of cannabis using patches and creams
- Mucus topical cannabis delivery through buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository
- Inhalation delivery of cannabis for topic or systemic applications
These latest provisional patent filings join an established number of global rights to topical, oral, transdermal, food and beverage patented technologies that Pivot has already secured.
A case in point is Pivot’s recent acquisition of the BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids. Oral delivery of cannabinoids can produce inconsistent absorption efficiencies and unfavorable side effects, while topical delivery technologies often suffer from weak formulation issues. By contrast, transdermal delivery has greater potential to produce a more favorable outcome without the negative side effects and absorption issues. Another benefit of transdermal delivery is that it enables patients to apply medication over a prolonged period with fewer side effects than with other methods of delivery. The BiPhasix™ delivery system, thoroughly tested in clinical trials approved by the FDA and EMA, was demonstrated to enhance the bioavailability of drugs and to improve clinical outcomes.
Pivot Pharmaceuticals also created subsidiary Pivot Green Stream Health Solutions Inc. to focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream will develop natural cannabinoid-based health products that qualify for the Natural Health Product (NHP) designation conferred by Health Canada.
In addition, Pivot has acquired the global rights from Solmic GmbH for the development and commercialization of the Solmic Solubilization Technology Platform. This formulation technology provides significantly higher bioavailability of active ingredients while masking unpleasant tastes and smells. This oral delivery platform greatly increases uptake of fat-soluble ingredients from the gut into the blood system, resulting in increased bioavailability.
The company has several products in its development pipeline which target cancer supportive care, pain and inflammation, dermatology and eye disease. They include PGS-N005, a cannabinoid-based topical cream to treat female sexual dysfunction. This formulation will treat hypoactive sexual desire disorder, aimed specifically at peri-menopausal, menopausal and post-menopausal women with a decline in sexual desire and response. It is estimated that up to 63 percent of women in the United States may be affected by this disorder, with the female sexual dysfunction market estimated to exceed $4 billion.
Pivot Pharmaceuticals has a seasoned management team with extensive clinical, product development, commercial and financial experience. The company has positioned itself to be a crucial vertical in the cannabis industry, with a focus on biotechnological development. As part of its business strategy, Pivot works with licensed producers (LPs) and licensed dealers (LDs) to bring new therapies to the market.
For more information, visit the company’s website at www.PivotPharma.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com